GB201516971D0 - MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells - Google Patents

MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells

Info

Publication number
GB201516971D0
GB201516971D0 GBGB1516971.7A GB201516971A GB201516971D0 GB 201516971 D0 GB201516971 D0 GB 201516971D0 GB 201516971 A GB201516971 A GB 201516971A GB 201516971 D0 GB201516971 D0 GB 201516971D0
Authority
GB
United Kingdom
Prior art keywords
cells
mvd
identification
epigenetic marker
immune cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1516971.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision for Medicine GmbH
Original Assignee
Epiontis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epiontis GmbH filed Critical Epiontis GmbH
Priority to GBGB1516971.7A priority Critical patent/GB201516971D0/en
Publication of GB201516971D0 publication Critical patent/GB201516971D0/en
Priority to JP2018512289A priority patent/JP2018534910A/ja
Priority to CN201680052340.6A priority patent/CN108026577B/zh
Priority to HK19100073.9A priority patent/HK1257705A1/zh
Priority to EP16770485.7A priority patent/EP3353321B1/en
Priority to CA2995350A priority patent/CA2995350A1/en
Priority to US15/752,048 priority patent/US11788141B2/en
Priority to PCT/EP2016/072522 priority patent/WO2017050882A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB1516971.7A 2015-09-25 2015-09-25 MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells Ceased GB201516971D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1516971.7A GB201516971D0 (en) 2015-09-25 2015-09-25 MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells
JP2018512289A JP2018534910A (ja) 2015-09-25 2016-09-22 免疫細胞、特にｃｄ５６＋ ｎｋ細胞の同定のためのエピジェネティックマーカーとしてのｍｖｄ
CN201680052340.6A CN108026577B (zh) 2015-09-25 2016-09-22 Mvd作为用于鉴定免疫细胞特别是cd56+nk细胞的表观遗传标志物
HK19100073.9A HK1257705A1 (zh) 2015-09-25 2016-09-22 Mvd作为用於鉴定免疫细胞特别是cd56+ nk细胞的表观遗传标志物
EP16770485.7A EP3353321B1 (en) 2015-09-25 2016-09-22 Mvd as epigenetic marker for the identification of cd56+ nk cells
CA2995350A CA2995350A1 (en) 2015-09-25 2016-09-22 Mvd as epigenetic marker for the identification of immune cells, in particular cd56+ nk cells
US15/752,048 US11788141B2 (en) 2015-09-25 2016-09-22 MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells
PCT/EP2016/072522 WO2017050882A1 (en) 2015-09-25 2016-09-22 Mvd as epigenetic marker for the identification of immune cells, in particular cd56+ nk cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1516971.7A GB201516971D0 (en) 2015-09-25 2015-09-25 MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells

Publications (1)

Publication Number Publication Date
GB201516971D0 true GB201516971D0 (en) 2015-11-11

Family

ID=54544101

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1516971.7A Ceased GB201516971D0 (en) 2015-09-25 2015-09-25 MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells

Country Status (8)

Country Link
US (1) US11788141B2 (OSRAM)
EP (1) EP3353321B1 (OSRAM)
JP (1) JP2018534910A (OSRAM)
CN (1) CN108026577B (OSRAM)
CA (1) CA2995350A1 (OSRAM)
GB (1) GB201516971D0 (OSRAM)
HK (1) HK1257705A1 (OSRAM)
WO (1) WO2017050882A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017125013B4 (de) * 2017-10-25 2019-10-17 Epiontis Gmbh MCC als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere basophiler Granulozyten
DE102018112644B4 (de) 2018-05-25 2020-06-10 Epiontis Gmbh CXCR3 als epigenetischer Marker zur Identifizierung von inflammatorischen Immunzellen, insbesondere CD8+ Gedächnis-T-Zellen
DE102018116353B4 (de) * 2018-07-05 2020-06-10 Epiontis Gmbh Verfahren zum Nachweis und zur Zählung epigenetischer Immunzellen in humanen Blutproben für Immundiagnostik und Neugeborenen-Screening
CN119372341B (zh) * 2024-12-30 2025-04-11 北京致谱医学检验实验室有限公司 基于基因甲基化检测实现人nk淋巴细胞计数的试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH2220H1 (en) * 2001-08-10 2008-07-01 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US20070243161A1 (en) * 2006-02-28 2007-10-18 Sven Olek Epigenetic modification of the loci for CAMTA1 and/or FOXP3 as a marker for cancer treatment
EP2878680B1 (en) * 2008-07-09 2016-06-08 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
PL2248913T3 (pl) * 2009-04-28 2017-04-28 Epiontis Gmbh GNLY jako marker epigenetyczny do identyfikacji komórek naturalnej cytotoksyczności ekspresjonujących CD56
CN102343086A (zh) * 2010-05-28 2012-02-08 四川大学 治疗或预防肿瘤的药物、肿瘤全细胞疫苗及其制备方法和用途
JP6010037B2 (ja) * 2010-10-08 2016-10-19 エピオンティス ゲーエムベーハー 腫瘍浸潤全ｔリンパ球の分析に基づいて、がん患者の生存指標を測定する方法
GB201112586D0 (en) 2011-07-22 2011-09-07 Epiontis Gmbh Epigenetic marker for the identification of natural killer cells
WO2013033627A2 (en) * 2011-09-01 2013-03-07 The Regents Of The University Of California Diagnosis and treatment of arthritis using epigenetics

Also Published As

Publication number Publication date
EP3353321B1 (en) 2020-11-04
WO2017050882A1 (en) 2017-03-30
CN108026577A (zh) 2018-05-11
JP2018534910A (ja) 2018-11-29
CN108026577B (zh) 2022-09-23
US20180237855A1 (en) 2018-08-23
HK1257705A1 (zh) 2019-10-25
US11788141B2 (en) 2023-10-17
EP3353321A1 (en) 2018-08-01
CA2995350A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
IL290678B1 (en) New crispr enzymes and systems
IL271239A (en) A method for developing nucleic acids
PL3113883T3 (pl) Układ sortujący komórki z wykorzystaniem mikrofabrykowanych składowych
GB201619969D0 (en) Battery system
GB201611982D0 (en) Cell culture
GB201610515D0 (en) Cell
HUE051624T2 (hu) Akkumulátor rendszer
PL3331055T3 (pl) Układ akumulatora zawierający wymienne nośniki komponentów akumulatora
GB201503500D0 (en) Cell
GB201621889D0 (en) Cell
HUE066020T2 (hu) Sejt
GB201522097D0 (en) Cells
PL3490096T3 (pl) Układ akumulatorów
GB201603088D0 (en) Cell sorting
GB201616238D0 (en) Modified T cells
GB201603372D0 (en) Cell
GB201408841D0 (en) Nucleic acid processing
IL266111A (en) Methods for inducing a t-cell response
ZA201900891B (en) B-cell-mimetic cells
GB201516972D0 (en) LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells
GB201609604D0 (en) Cell
GB201516975D0 (en) PARK2 as epigenetic marker for the identification of immune cells, in particular monocytes
EP3394787C0 (en) IMPROVED MEMORY SYSTEM
GB201617716D0 (en) Cell
PL3287521T3 (pl) Hodowla komórkowa

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)